Corporate

  • Mar. 31, 2021 Bioasis Technologies Inc. and Aposense Enter into a Research Collaboration

    NEW HAVEN, Conn., March 31, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain… Read more »

  • Mar. 29, 2021 Bioasis Announces Publication of CNS Delivery of siRNA via xB³ ™ Platform Technology

    NEW HAVEN, Conn., March 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »

  • Mar. 24, 2021 Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing

    NEW HAVEN, Conn., March 24, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF;), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and… Read more »

  • Mar. 22, 2021 Bioasis Technologies Inc. Announces Warrant Extension and Repricing

    NEW HAVEN, Conn., March 22, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”) a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ?™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers… Read more »

  • Dec. 10, 2020 Bioasis Announces Annual General Meeting Results

    GUILFORD, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »

  • Dec. 3, 2020 Platform Technology – Overcoming the Challenges of Drug Brain Delivery With a Novel Brain Delivery Vector

    Latest publication on Bioasis’ leading BBB drug delivery technology by Dr. Mei Mei Tian, our Head of External Research.

  • Nov. 10, 2020 Bioasis Announces Annual General Meeting Details

    GUILFORD, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »

  • Jun. 29, 2020 Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance

    Deal provides Chiesi Group with worldwide, exclusive license to use Bioasis xB3 TM platform for delivery of undisclosed enzymes in treatment of four lysosomal storage disorders. Under terms of the agreement, Bioasis will receive an upfront payment of US$3 million, additional potential milestone payments of up to US$138 million and royalties on net sales from… Read more »

  • Mar. 4, 2020 Bioasis Technologies Announces the Appointment of Dr. May Orfali to the Position of Consultant Chief Medical Officer

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced… Read more »

  • Dec. 23, 2019 Bioasis Completes Bridge Financing Transaction

    This News Release Is Intended for Distribution in Canada Only and Is Not Intended for Distribution to United States Newswire Services or Dissemination in the United States GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”) a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of… Read more »